Catalent Inc (NASDAQ:CTLT) shot up 1.3% on Wednesday . The stock traded as high as $25.46 and last traded at $25.39, with a volume of 209,230 shares trading hands. The stock had previously closed at $25.07.

Several research firms recently weighed in on CTLT. Zacks Investment Research lowered Catalent from a “hold” rating to a “strong sell” rating in a research report on Monday, August 15th. Jefferies Group restated a “hold” rating on shares of Catalent in a research report on Thursday, August 4th. Wells Fargo & Co. upgraded Catalent from a “market perform” rating to an “outperform” rating in a research report on Tuesday, June 21st. Bank of America Corp. upgraded Catalent from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a research report on Monday, June 20th. They noted that the move was a valuation call. Finally, TheStreet upgraded Catalent from a “sell” rating to a “hold” rating in a research report on Wednesday, August 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $27.67.

The company has a market cap of $3.15 billion and a price-to-earnings ratio of 15.69. The company has a 50 day moving average of $24.96 and a 200-day moving average of $25.60.

Catalent (NASDAQ:CTLT) last posted its quarterly earnings data on Monday, August 29th. The company reported $0.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.53 by $0.01. The firm earned $532.20 million during the quarter. During the same period last year, the business posted $0.61 earnings per share. Catalent’s quarterly revenue was up 4.3% compared to the same quarter last year. On average, analysts anticipate that Catalent Inc will post $1.39 EPS for the current fiscal year.

In other news, major shareholder Blackstone Management Associat sold 8,785,539 shares of the firm’s stock in a transaction that occurred on Thursday, June 9th. The stock was sold at an average price of $24.51, for a total value of $215,333,560.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Catalent, Inc is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Company’s segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.